Session Information
Session Type: ACR Poster Session C
Session Time: 9:00AM-11:00AM
Background/Purpose:
Behcet’s disease (BD) is a systemic vasculitis disorder of unknown etiology with recurrent exacerbations and remissions. The etiopathogenesis of the disease is still unclear. The most investigated cytokine in the pathogenesis of the disease is interleukin (IL) -1 family. A new member of the IL-1 cytokine family, IL-36Ra (Receptor Antagonist), stimulates dendritic cells from the host cells of innate and acquired immunity. In this study we investigated whether the level of serum IL-36Ra increase or not in the etiopathogenesis of Behcet’s disease, its effect on disease activity and clinical findings.
Methods:
Serum IL-36Ra levels were measured by (ELISA) kits following the manufacturer’s instructions. All BD patients recruited for this study met the 1990 international criteria for classification of BD.
Results:
31 of the patients were active disease (51.7%). Demographic and clinical parameters are shown in Table 1.
Table 1: Demographic and clinical characteristics of Behcet’s patients and healthy controls
| Parameter | All BD Patients (n:60) | Active BD Patients (n:31) |
Healthy Controls (n:20) |
| Age (year) | 41 ± 11,1 (mean+SD) | 38,4 ± 11,3 | 40,2 ± 13 |
| Sex (M/F) | 29/31 | 14/17 | 10/10 |
| Oral ulcers | 59 (98.3%) | 25 (80.6%) | – |
| Genital ulcers | 48 (80%) | 23 (74.2%) | – |
| Thrombophlebitis | 14 (23.3%) | 7 (22.6%) | – |
| Arthritis | 22 (36.6%) | 11 (35.5%) | – |
| Uveitis | 30 (50%) | 11 (35.5%) | – |
| Deep vein thrombosis | 18 (30%) | 6 (19.4%) | – |
| CNS involvement | 5 (8.3%) | 4 (12.9%) | – |
Serum IL-36Ra levels were found to be 15.36 ± 13.26 pg / ml in the patient group and 17.90 ± 13.03 pg / ml in the control group (p = 0.677). Serum IL-36Ra levels were found to be 17.80 ± 10.63 pg / ml in the active patient group and serum IL-36 Ra level in the inactive patient group was found to be 12.77 ± 7.12 pg / ml. A statistically significant difference was found between IL-36Ra levels in active and inactive patient groups (p = 0.037). There was no statistically significant difference between IL-36Ra levels (p = 0.636 and p = 0.207, respectively) between active patient and inactive patient group and control group. Serum IL-36Ra levels were significantly higher in patients with Behçet’s disease than those without oral ulcers (p = 0.018). In addition, serum IL-36Ra levels (24.45 ± 11.58 pg / ml) were higher in patients with neurological involvement than those without neurological involvement (14.45 ± 8.71 pg / ml) (p = 0.011). No statistically significant difference was found between serum IL-36Ra and other systemic manifestations.
Conclusion:
According to our results, there was a statistically significant difference between IL-36Ra and oral ulcers, neurological involvement, disease activity and CRP. More study is needed to determine the role of IL-36Ra in the pathogenesis of Behcet’s disease.
To cite this abstract in AMA style:
Ünsal P, Cerci P, Açıkgöz ŞA, Keskin G, Ölmez Ü. Serum Levels of Interleukin-36 Receptor Antagonist in Behçet’s Patients [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/serum-levels-of-interleukin-36-receptor-antagonist-in-behcets-patients/. Accessed .« Back to 2017 ACR/ARHP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/serum-levels-of-interleukin-36-receptor-antagonist-in-behcets-patients/